DBTX Stock Price, Decibel Therapeutics, . Quote, Chart

DBTX Stock Price

View Fullscreen

DBTX RSI Chart

DBTX Valuation

Market Cap

123.4M

Price/Earnings (Trailing)

-1.95

EV/EBITDA

-1.35

Price/Free Cashflow

-2.5

MarketCap/EBT

-1.95

DBTX Price/Earnings (Trailing)

DBTX Profitability

Return on Equity

-118.91%

Return on Assets

-67.16%

Free Cashflow Yield

-39.96%

DBTX Fundamentals

DBTX Earnings

Earnings (TTM)

-63.4M

Earnings Growth (Yr)

-6.45%

Earnings Growth (Qtr)

-36.39%

Breaking Down DBTX Revenue

Last 7 days

-3.7%

Last 30 days

-2.2%

Last 90 days

23.4%

Trailing 12 Months

-2%

How does DBTX drawdown profile look like?

DBTX Financial Health

Current Ratio

3.03

DBTX Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

-2.54

Tracking the Latest Insider Buys and Sells of Decibel Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 25, 2023	nochur sara	back to issuer	-	-	-5,000	-
Sep 25, 2023	lee john jui-jen	back to issuer	-	-	-147,144	chief development officer
Sep 25, 2023	trask anna	back to issuer	-	-	-106,864	chief people officer
Sep 25, 2023	carson william h.	back to issuer	-	-	-5,000	-
Sep 25, 2023	finger alison cecily	back to issuer	-	-	-5,000	-
Sep 25, 2023	kapusta matthew c	back to issuer	-	-	-10,000	-
Sep 25, 2023	reid laurence	back to issuer	-	-	-220,849	see remarks
Sep 25, 2023	mclaughlin kevin f	back to issuer	-	-	-5,000	-
Jun 13, 2023	nochur sara	acquired	-	-	5,000	-
Jun 13, 2023	mclaughlin kevin f	acquired	-	-	5,000	-

Which funds bought or sold DBTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	ATLAS CAPITAL ADVISORS LLC	sold off	-100	-36,400	-	-%

Are Funds Buying or Selling DBTX?

Are funds buying DBTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DBTX

No. of Funds

Unveiling Decibel Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	0.0%	0	SC 13G/A
Sep 27, 2023	regeneron pharmaceuticals, inc.	100%	100	SC 13D/A
Aug 18, 2023	regeneron pharmaceuticals, inc.	8.3%	2,097,314	SC 13D
Feb 14, 2023	citadel advisors llc	7.1%	6	SC 13G/A
Feb 03, 2023	blackrock inc.	7.2%	1,805,108	SC 13G
Feb 14, 2022	gv 2016, l.p.	1.29%	321,978	SC 13G
Feb 14, 2022	third rock ventures iii, l.p.	12.6%	3,139,685	SC 13G
Feb 14, 2022	citadel advisors llc	7.1%	6	SC 13G/A
Feb 11, 2022	regeneron pharmaceuticals, inc.	8.42%	2,097,314	SC 13G

Recent SEC filings of Decibel Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Feb 14, 2024	SC 13G/A	Major Ownership Report

Decibel Therapeutics, Inc. News

Latest updates

Decibel Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-14.5%	94.00	110	123	142	158	174	184	185	197	207	67.00
Current Assets	-16.1%	80.00	96.00	108	126	141	151	164	150	161	191	58.00
Cash Equivalents	4.6%	40.00	38.00	35.00	37.00	56.00	11.00	36.00	51.00	38.00	52.00	28.00
Net PPE	-6.9%	4.00	4.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00
Liabilities	1.1%	41.00	41.00	42.00	45.00	46.00	46.00	43.00	31.00	27.00	27.00	29.00
Current Liabilities	14.7%	27.00	23.00	22.00	23.00	23.00	18.00	21.00	16.00	17.00	15.00	19.00
Shareholder's Equity	-23.7%	53.00	70.00	82.00	97.00	112	128	142	154	169	180	-
Retained Earnings	-6.2%	-308	-290	-277	-261	-245	-228	-214	-201	-185	-173	-162
Additional Paid-In Capital	0.4%	362	361	360	359	358	357	356	356	355	354	108
Shares Outstanding	0.4%	25.00	25.00	25.00	25.00	25.00	25.00	25.00	21.00	19.00	12.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	39.8%	-10,268	-17,056	-7,766	-13,717	-13,408	-22,007	-9,545	-11,650	-5,649	-16,306	-5,149	-7,682	-7,924	-11,906
Share Based Compensation	40.5%	1,373	977	637	876	845	842	371	1,036	764	646	2,225	185	179	225
Cashflow From Investing	-42.1%	11,772	20,317	5,648	-5,998	59,063	-3,616	-5,564	25,322	-8,310	-112,443	-26,694	82.00	1,905	11,694
Cashflow From Financing	4.6%	206	197	-55.00	-54.00	-52.00	-52.00	151	51.00	-840	153,148	-	-	-	-

DBTX Income Statement

2023-06-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 12,828	$ 11,241	$ 20,762	$ 18,707
General and administrative	6,213	5,862	12,400	12,415
Total operating expenses	19,041	17,103	33,162	31,122
Loss from operations	(19,041)	(17,103)	(33,162)	(31,122)
Other income:
Interest income	976	95	1,854	158
Total other income, net	976	95	1,854	158
Net loss before provision for income taxes	(18,065)	(17,008)	(31,308)	(30,964)
Provision for income taxes	(80)	(38)	(141)	(98)
Net loss	$ (18,145)	$ (17,046)	$ (31,449)	$ (31,062)
Net loss per share, basic	$ (0.73)	$ (0.68)	$ (1.26)	$ (1.24)
Net loss per share, diluted	$ (0.73)	$ (0.68)	$ (1.26)	$ (1.24)
Weighted average shares of common stock outstanding, basic	25,017,851	24,958,678	25,003,634	24,956,932
Weighted average shares of common stock outstanding, diluted	25,017,851	24,958,678	25,003,634	24,956,932
Comprehensive loss:
Net loss	$ (18,145)	$ (17,046)	$ (31,449)	$ (31,062)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities, net of tax of $0	26	(61)	188	(456)
Total other comprehensive income (loss)	26	(61)	188	(456)
Comprehensive loss	$ (18,119)	$ (17,107)	$ (31,261)	$ (31,518)

DBTX Balance Sheet

2023-06-30

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 39,803	$ 34,607
Available-for-sale securities	38,497	69,954
Prepaid expenses and other current assets	2,149	3,469
Total current assets	80,449	108,030
Property and equipment, net	3,960	4,526
Right-of-use asset, operating	8,948	9,859
Right-of-use asset, finance	96	34
Other assets	934	924
Total assets	94,387	123,373
Current liabilities:
Accounts payable	617	1,064
Accrued expenses and other current liabilities	10,291	8,409
Deferred collaboration liability, current	12,007	9,383
Operating lease liability, current	3,612	3,567
Finance lease liability, current	51	19
Total current liabilities	26,578	22,442
Long-term liabilities:
Deferred collaboration liability, long term	3,399	6,765
Operating lease liability, long-term	9,138	10,467
Finance lease liability, long-term	46
Other long-term liabilities	1,914	1,906
Total liabilities	41,075	41,580
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, $0.001 par value; 200,000,000 shares authorized, 25,126,935 shares issued and outstanding at June 30, 2023; 200,000,000 shares authorized, 24,964,502 shares issued and outstanding at December 31, 2022	25	25
Additional paid-in capital	362,288	359,508
Accumulated other comprehensive loss	(35)	(223)
Accumulated deficit	(308,966)	(277,517)
Total stockholders' equity	53,312	81,793
Total liabilities and stockholders' equity	$ 94,387	$ 123,373

About Decibel Therapeutics, Inc.

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

CEO	Dr. Laurence E. Reid Ph.D.
WEBSITE	decibeltx.com
INDUSTRY	Biotechnology
EMPLOYEES	68

Decibel Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Decibel Therapeutics, Inc.? What does DBTX stand for in stocks?

DBTX is the stock ticker symbol of Decibel Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Decibel Therapeutics, Inc. (DBTX)?

As of Fri Sep 22 2023, market cap of Decibel Therapeutics, Inc. is 123.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DBTX stock?

You can check DBTX's fair value in chart for subscribers.

What is the fair value of DBTX stock?

You can check DBTX's fair value in chart for subscribers. The fair value of Decibel Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Decibel Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DBTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Decibel Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether DBTX is over valued or under valued. Whether Decibel Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Decibel Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DBTX.